Endoscopic Retrograde Cholangiopancreatography Market

Market Overview

The global endoscopic retrograde cholangiopancreatography market size was valued at USD 1219.4 million in 2021. It is projected to reach USD 2,229.94 million by 2030, growing at a CAGR of 7% during the forecast period (2022–2030).

The diagnostic and therapeutic procedure known as endoscopic retrograde cholangiopancreatography, or ERCP, combines X-ray imaging with upper gastrointestinal (GI) endoscopy to diagnose and treat conditions affecting the bile and pancreatic ducts. The tubes that transport bile from the liver to the gallbladder and then to the duodenum are called bile ducts. These passageways transport pancreatic juice from the duodenum to the pancreatic. When bile or pancreatic ducts have become narrowed or blocked, an ERCP procedure may be recommended by a doctor. This may result from gallstones, infection, acute pancreatitis, chronic pancreatitis, pancreatic pseudocysts, cancers of the bile ducts and pancreas, or other conditions.

Endoscopic retrograde cholangiopancreatography (ERCP) is a diagnostic procedure for diseases affecting the gallbladder, biliary system, pancreas, and liver. ERCP devices use a combination of fluoroscopic imaging and luminal endoscopy to diagnose and treat disorders related to the pancreaticobiliary system. Endotherapy devices are commonly used to treat conditions such as Barrett's disease, biliary disease, colitis, Crohn's disease, gastroesophageal reflux disease (GERD), liver disease, pancreatitis, and inflammatory bowel disease, and peptic ulcer disease.

Market Dynamics

Market Driving Factors

Rising Number of People Suffering from Digestive and Chronic Biliary Disorders to Propel Growth

An increase in the prevalence of chronic conditions, the most common of which are Barrett's Disease., Biliary Disease, Colitis, Crohn's Disease, Gastroesophageal Reflux Disorder (GERD), liver Disease, Pancreatitis, Inflammatory Bowel Disease, and Peptic Ulcer Disease. The most common conditions that make it difficult for patients to go about their daily lives are chronic gastrointestinal and biliary conditions. It is anticipated that an increase in the prevalence of diseases will drive an increase in the demand for treatment, which is anticipated to drive the growth of the market for endoscopic retrograde cholangiopancreatography.

Increase In Frequencies of Benign Tumors to Foster Market Growth

Endoscopic retrograde cholangiopancreatography (ERCP) is experiencing a rapid and continuous increase in the number of devices for diagnosing and treating benign liver and pancreas tumors. Some examples of these benign tumors include comorbidities adenomas, hemangiomas, and focal nodular hyperplasia (FNH). The leading rivals in this market, Olympus Corporation, Hobbs Medical, Inc., Telemed System, Inc., and Becton, Dickinson, and Company, list pancreatic adenocarcinoma as additional benign pancreatic tumors.

Increase in the Older Population to Boost Market Progress

As the world's population ages faster, there has been a corresponding surge in the number of endoscopic devices used in the field of ERCP. The aging of the population is causing a significant rise in the incidence of visual impairment. As a result, comorbidities like adenomas, hemangiomas, focal nodular hyperplasia (FNH), and pancreatic adenocarcinoma have been observed. Cancer of the pancreas is the leading cause of death from the fourth most common type of cancer worldwide. According to the National Cancer Database, in the United States, those over 65 make up 68.5% of those diagnosed with pancreatic cancer. Oncologists will see an increasing number of elderly patients with gastrointestinal and chronic biliary disorders and benign liver and pancreas tumors as the elderly population continues to grow. In the coming years, it is anticipated that this will contribute positively to the expansion of the ERCP market.

Market Restraining Factors

High Costs Associated with Treatment from ERCP Devices to Restrict Market Growth

Upper gastrointestinal (GI) endoscopy and x-rays are components of the ERCP procedure, which diagnose and treat conditions affecting the bile and pancreatic ducts. High treatment costs are associated with ERCP devices, including sphincterotomes, lithotripters, endoscopes, accessories, stents, cannulas, forceps, snares, catheters, guide wires, balloons, and baskets. These high costs are a significant barrier to the expansion of the market. For endoscopic retrograde cholangiopancreatography (ERCP) diagnostic procedures, disposable equipment accounted for 27% of reimbursement, whereas for ERCP therapeutic procedures, disposable equipment accounted for 68% of reimbursement. Although reimbursement for therapeutic ERCP was higher overall, this was partially offset by the high direct costs associated with disposable equipment, which limited reimbursement's ability to cover indirect costs. Therefore, a rise in the prevalence of disorders alongside an increase in the high costs associated with the treatment provided by ERCP devices is anticipated to reduce the impact and limit the market growth in the future.

Key Market Opportunities

Rising Awareness Worldwide to Boost Market Opportunities

The endoscopic retrograde cholangiopancreatography market is experiencing a rapid and continuous increase in diagnosing devices due to comorbidities adenomas, hemangiomas, focal nodular hyperplasia (FNH), Pancreatic adenocarcinoma, Ampullary cancer, and others. An increase in the disorder related to pancreatic, liver, and bile ducts leads to a surge in awareness of ERCP devices. This provides growth opportunities to the manufacturers, thus boosting the market growth.

Regional Analysis

The global endoscopic retrograde cholangiopancreatography market is divided into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

North America is the highest revenue contributor to the global endoscopic retrograde cholangiopancreatography market and is estimated to reach USD 766.03 million by 2030, growing at a CAGR of 7.4% during the forecast period. North America's market of endoscopic retrograde cholangiopancreatography contributed the largest share to the overall total. The United States is responsible for the highest number of endoscopic retrograde cholangiopancreatography (ERCP) procedures in the region where endoscopes, endotherapy devices, imaging systems, and energy devices are utilized. It is anticipated that this will provide a significant opportunity for businesses operating in the market of endoscopic retrograde cholangiopancreatography to grow their customer base and revenue.

Europe is ERCP's second most lucrative market. This can be attributed to the significant burden that pancreatic and bile disorders place on people's overall health. These conditions include gastroesophageal reflux disease (GERD), liver disease, pancreatitis, inflammatory bowel disease, and Crohn's disease. In severe cases, surgical intervention is required to treat these conditions when the diseases have not been detected in their earlier stages. Given that there are untapped markets for ERCP products and pancreatic cancer is more prevalent there, Germany now controls most of the European market for endoscopic retrograde cholangiopancreatography devices.

The Chinese market dominated the Asia Pacific. Because of Japan's advanced healthcare system, which includes universal health insurance coverage, this region's market has experienced rapid expansion. Countries like China and India concentrated on enhancing medical infrastructure to treat many people with severe illnesses like cancer and tumors. Additionally, growth in the number of endoscopic retrograde cholangiopancreatography (ECRP) equipment makers is expected to increase demand for ECRP devices.

Europe is ERCP's second most lucrative market. This can be attributed to the significant burden that pancreatic and bile disorders place on people's overall health. These conditions include gastroesophageal reflux disease (GERD), liver disease, pancreatitis, inflammatory bowel disease, and Crohn's disease. In severe cases, surgical intervention is required to treat these conditions when the diseases have not been detected in their earlier stages.

Segmental Analysis

The global endoscopic retrograde cholangiopancreatography market is segmented by product, application, and end-user

By Product Type

Based on product type, the global market of endoscopic retrograde cholangiopancreatography is categorized into endoscopes, endotherapy devices, imaging systems, energy devices, and others.

The endoscopes segment is the highest contributor to the market, growing at a CAGR of 8.8% during the forecast period. Due to an increase in gastrointestinal and chronic biliary disorders, the market for endoscopic retrograde cholangiopancreatography devices for endoscopes is expected to expand significantly over the coming years. According to the World Health Organization, approximately 8 million deaths yearly are caused by gastrointestinal (GI) diseases. Thus, an increase in the disorders related to bile duct liver and pancreatic cancer is anticipated to increase the demand for the product in the market. Further, it creates a significant opportunity for endoscopic retrograde cholangiopancreatography device manufacturers to expand their business worldwide.  In addition, an increase in health care expenditures and favorable administration regulations are anticipated to stimulate the market's growth in the coming years.

By Application

Based on application, the global market of endoscopic retrograde cholangiopancreatography is categorized into biliary sphincterotomy, biliary dilatation, biliary stenting, pancreatic sphincterotomy, pancreatic duct dilatation, and pancreatic duct stenting.

The biliary sphincterotomy segment is the highest contributor to the market, growing at a CAGR of 8.1% during the forecast period. A high-frequency current is used to cut the biliary sphincter and the intraduodenal segment of the common bile duct after selective cannulation with a special knife called a sphincterotome inserted into the papilla. This procedure is called biliary sphincterotomy or biliary endoscopic sphincterotomy (EST).

Due to the rising prevalence of obstructive ductal calculi, ductal disruption & leak, sphincter stenosis, and dominant pancreatic stricture in the population, the pancreatic sphincterotomy sector is anticipated to grow at the greatest CAGR throughout the forecast period. The market for endoscopic retrograde cholangiopancreatography is also expanding due to the surge in demand for endoscopic procedures used to treat various pancreatic and pancreas-related illnesses.

Due to the rising prevalence of obstructive ductal calculi, ductal disruption & leak, sphincter stenosis, and dominant pancreatic stricture in the population, the pancreatic sphincterotomy sector is anticipated to grow at the greatest CAGR throughout the forecast period. The market for endoscopic retrograde cholangiopancreatography is also expanding due to the surge in demand for endoscopic procedures used to treat various pancreatic and pancreas-related illnesses.

By End-User

Based on end-user, the global market             endoscopic retrograde cholangiopancreatography is segmented into hospitals, clinics, and ambulatory surgery centers.

The hospitals and clinics segment is the highest contributor to the market, growing at a CAGR of 7.8% during the forecast period. Ambulatory surgery centers, also known as ASCs, are specialized medical facilities that provide patients with the option of having surgical procedures and other treatments carried out outside a traditional hospital environment. The ambulatory surgical center's segment is expected to grow highest during the forecast period, owing to the prevalence of pancreatic cancer, bile duct, and pancreatic duct diseases. These factors are expected to foster the growth of the ERCP market.

Recent Developments

• In February 2023, a High-Throughput Single-Cell Multiomics Platform was Introduced by BD to Widen the Scope of Scientific Discovery.
• In February 2023, FDA approval for Boston Scientific's LithoVueTM Elite Single-Use Digital Flexible Ureteroscope System.
• In February 2023, The beginning of a new phase III clinical trial in Japan involving patients who have meniscus injuries has been announced by Fujifilm.